NITI Aayog Member for the Health sector Dr. VK Paul has said that the Drugs Controller General of India or DCGI is assessing the Covid-19 vaccine for kids manufactured by Gujarat-based Zydus Cadila. He said that India’s top drug regulator is examining the vaccine and more data is required. Dr. Paul added that the scientific process has to be over and viewed that the country has to be lucky that it should be effective and safe.
It was reported that Zydus Cadila’s Corona vaccine for children is likely to take some more time to be available as DCGI may take additional time for permitting it emergency use approval or EUA.
Early July, the domestic drug player had applied for EUA for its DNA Covid vaccine the ZyCoV-D for kids in 12 years and above age group to DCGI. It provided the interim results from the third phase of clinical trials carried out in 28,000-plus volunteers. The study reportedly demonstrated safety and efficacy in the interim data. Zydus Cadila is planning to produce 10 to 12 crore vaccine doses per year.
The company has reportedly said that the study was conducted during the peak of the Covid-19’s second wave in India. This reaffirms the efficacy of the vaccine against the new mutant strains, particularly the Delta variant.